TG Therapeutics Announces Special Protocol Assessment Agreement With The FDA for Its First Phase 3 Clinical Trial of TG-1101 In Combination With ImbruvicaF or Patients With Previously Treated Chronic Lymphocytic Leukemia
September 15, 2014 at 07:06 AM EDT
TG Therapeutics, Inc. (Nasdaq: TGTX) announced today that it has reached an agreement with the U.S. Food and Drug Administration (FDA) ...
